Crinetics Pharmaceuticals Inc CRNX

What could happen to the stock (~$33.70 now) if approved:
• Modest case: +15–30% → ~$39–43
• Base case: +30–50% → ~$43–50
• Bull case: +50–80% → ~$50–60+
• Home-run case: 100%+ → ~$65+

Why it could pop:
Approval removes uncertainty
Oral therapy is more convenient than injections
Orphan disease status → pricing & exclusivity advantages
Short interest could trigger a squeeze
Positive sentiment from analysts & media

What could limit upside:
Mainly label restriction.

Approval is likely to give CRNX a strong near-term boost, but exact moves depend on label, adoption, and market sentiment.